AI Prospecting for Vertex Pharmaceuticals
Company data:
Company size:
6100 employeesWebsite URL:
https://www.vrtx.comIndustry
BiotechnologyHeadquarters:
Boston, Massachusetts, USAInvestment round:
Publicly Traded (NASDAQ: VRTX)ARR:
$9 billionKey stakeholders
These are the current top-level decision-makers at the company and their LinkedIn profiles. Check them for recent activity and updates
Latest news about Vertex Pharmaceuticals
Here are some of the most recent media mentions. Use them in your sales prospecting to qualify a prospect's buyer intent and personalize outreach with the latest company updates
Vertex Pharmaceuticals will announce its first quarter 2025 financial results on May 5, 2025, after market close, with a conference call at 4:30 PM ET. Analysts estimate Q1 2025 non-GAAP EPS of $3.75, reflecting higher R&D spending and costs from the Alpine Immune Sciences acquisition[3][5].
Vertex researcher Paul Negulescu, Ph.D., has been awarded the 2025 Canada Gairdner International Award for pioneering research into the cellular and molecular mechanisms of cystic fibrosis[4].
Vertex Pharmaceuticals has announced the UK MHRA approval of ALYFTREK® (deutivacaftor/tezacaftor/vanzacaftor), a once-daily next-in-class CFTR modulator for the treatment of cystic fibrosis, as of March 7, 2025[2].
Open job positions at Vertex Pharmaceuticals
This company is actively hiring to fill these roles. Use this for sales prospecting if your solution assists, augments, or provides an alternative for the growing team and position.
Medical Affairs Digital Program Director
Director, HCP Marketing, US Kidney - Pove
Director, Patient Marketing, US Kidney - Pove
AI sales outreach emails you can send to Vertex Pharmaceuticals
